AKT1 and colonic neoplasm: In this regard, Regorafenib is known to inhibit the mitogen-activated protein kinase (MAPK) cascade but has a more modest effect on the PI3K/Akt signaling pathway [99], therefore CGA potentiates its effect by complementing the inhibition of this key signaling pathway in the pathogenesis of advanced colon cancer [97].